




RealRate

# PHARMACEUTICAL 2018

Moleculin Biotech Inc.  
Rank 184 of 349



RealRate

• Financial Strength Rankings using Artificial Intelligence

• [www.realrate.ai](http://www.realrate.ai)

The relative strengths and weaknesses of Moleculin Biotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Moleculin Biotech Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 322% points. The greatest weakness of Moleculin Biotech Inc. is the variable Net Income, reducing the Economic Capital Ratio by 93% points.

The company's Economic Capital Ratio, given in the ranking table, is -192%, being 86% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	8,302
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,215
Liabilities, Non-Current	0
Other Assets	11,148
Other Compr. Net Income	0
Other Expenses	2,566
Other Liabilities	150
Other Net Income	1,387
Property and Equipment	33
Research and Development	4,545
Revenues	9.0
Selling, General and Administrative Expense	4,090

Output Variable	Value in 1000 USD
Assets	19,483
Liabilities	2,365
Expenses	11,201
Stockholders Equity	17,118
Net Income	-9,805
Comprehensive Net Income	-9,805
Economic Capital Ratio	-192%